Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives
Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration. Nasal mucosa as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasop...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1999-4923/6/3/378 |
| _version_ | 1811185877663088640 |
|---|---|
| author | Yingying Xu Pak-Wai Yuen Jenny Ka-Wing Lam |
| author_facet | Yingying Xu Pak-Wai Yuen Jenny Ka-Wing Lam |
| author_sort | Yingying Xu |
| collection | DOAJ |
| description | Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration. Nasal mucosa as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasopharyngeal-associated lymphoid tissues (NALT). Different kinds of DNA vaccines are investigated to provide protection against respiratory infectious diseases including tuberculosis, coronavirus, influenza and respiratory syncytial virus (RSV) etc. DNA vaccines have several attractive development potential, such as producing cross-protection towards different virus subtypes, enabling the possibility of mass manufacture in a relatively short time and a better safety profile. The biggest obstacle to DNA vaccines is low immunogenicity. One of the approaches to enhance the efficacy of DNA vaccine is to improve DNA delivery efficiency. This review provides insight on the development of intranasal DNA vaccine for respiratory infections, with special attention paid to the strategies to improve the delivery of DNA vaccines using non-viral delivery agents. |
| first_indexed | 2024-04-11T13:36:41Z |
| format | Article |
| id | doaj.art-a62eb8dffd9c4273a6afa62135ccd273 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-04-11T13:36:41Z |
| publishDate | 2014-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-a62eb8dffd9c4273a6afa62135ccd2732022-12-22T04:21:26ZengMDPI AGPharmaceutics1999-49232014-07-016337841510.3390/pharmaceutics6030378pharmaceutics6030378Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery PerspectivesYingying Xu0Pak-Wai Yuen1Jenny Ka-Wing Lam2Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, 21 Sassoon Road, Hong Kong, ChinaDepartment of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, 21 Sassoon Road, Hong Kong, ChinaDepartment of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, 21 Sassoon Road, Hong Kong, ChinaIntranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration. Nasal mucosa as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasopharyngeal-associated lymphoid tissues (NALT). Different kinds of DNA vaccines are investigated to provide protection against respiratory infectious diseases including tuberculosis, coronavirus, influenza and respiratory syncytial virus (RSV) etc. DNA vaccines have several attractive development potential, such as producing cross-protection towards different virus subtypes, enabling the possibility of mass manufacture in a relatively short time and a better safety profile. The biggest obstacle to DNA vaccines is low immunogenicity. One of the approaches to enhance the efficacy of DNA vaccine is to improve DNA delivery efficiency. This review provides insight on the development of intranasal DNA vaccine for respiratory infections, with special attention paid to the strategies to improve the delivery of DNA vaccines using non-viral delivery agents.http://www.mdpi.com/1999-4923/6/3/378DNA vaccineintranasal deliveryinfectious diseasesrespiratory pathogensadjuvantsmucosal |
| spellingShingle | Yingying Xu Pak-Wai Yuen Jenny Ka-Wing Lam Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives Pharmaceutics DNA vaccine intranasal delivery infectious diseases respiratory pathogens adjuvants mucosal |
| title | Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives |
| title_full | Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives |
| title_fullStr | Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives |
| title_full_unstemmed | Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives |
| title_short | Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives |
| title_sort | intranasal dna vaccine for protection against respiratory infectious diseases the delivery perspectives |
| topic | DNA vaccine intranasal delivery infectious diseases respiratory pathogens adjuvants mucosal |
| url | http://www.mdpi.com/1999-4923/6/3/378 |
| work_keys_str_mv | AT yingyingxu intranasaldnavaccineforprotectionagainstrespiratoryinfectiousdiseasesthedeliveryperspectives AT pakwaiyuen intranasaldnavaccineforprotectionagainstrespiratoryinfectiousdiseasesthedeliveryperspectives AT jennykawinglam intranasaldnavaccineforprotectionagainstrespiratoryinfectiousdiseasesthedeliveryperspectives |